EICHORPublic-registry site landscape for NCT04731467, “A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors”, a Solid Tumor study sponsored by Famewave Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04731467 (registry record) |
| Study title | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors |
| Official title | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors |
| Sponsor | Famewave Ltd. |
| Condition(s) | Solid Tumor; Non Small Cell Lung Cancer; Pancreatic Cancer; Ovarian Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 18 |
| Intervention(s) | CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion |
| Site countries | United States, Israel, Spain |
Patient-friendly overview of this study: eichor.com/study/NCT04731467.
Eichor generates a preliminary site-risk snapshot for NCT04731467 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
